Rapport Therapeutics, Inc. (RAPP), a pivotal player in the biotechnology sector, has recently caught the eye of investors with its impressive potential upside of 73.63%. As a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, Rapport Therapeutics is dedicated to developing transformative small molecule medicines targeting central nervous system (CNS) disorders.

The company, with a market capitalization of $1.41 billion, is on a mission to address unmet medical needs through innovative solutions. Its flagship product candidate, RAP-219, is engineered to inhibit TARPy8-containing AMPARs with extraordinary precision. This investigational small molecule stands at the forefront of treating focal epilepsy…